The CCT6B antibody is designed to target the CCT6B (Chaperonin Containing TCP1 Subunit 6B) protein, a member of the chaperonin-containing TCP-1 (CCT) complex. This evolutionarily conserved complex, also known as TRiC, assists in the folding of newly synthesized polypeptides, particularly actin and tubulin, essential for cytoskeletal integrity and cellular processes. CCT6B, one of eight paralogous subunits (CCT1–8), plays a critical role in substrate recognition and ATP hydrolysis, enabling conformational changes necessary for protein folding.
CCT6B is ubiquitously expressed but shows tissue-specific enrichment, notably in testis, suggesting a role in spermatogenesis. Dysregulation of CCT6B has been implicated in cancers, including hepatocellular carcinoma and glioblastoma, where its overexpression correlates with tumor progression and poor prognosis. Additionally, mutations in CCT6B are linked to neurodevelopmental disorders, highlighting its importance in neuronal function.
Antibodies against CCT6B are widely used in research to study its expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and co-immunoprecipitation. These tools help elucidate mechanisms underlying protein misfolding diseases, cancer biology, and reproductive health. Recent studies also explore CCT6B's potential as a therapeutic target, particularly in malignancies dependent on proper cytoskeletal dynamics. However, challenges remain in distinguishing CCT6B-specific functions from those of other CCT subunits due to structural and functional overlap within the complex.